Trial Profile
Feasibility and safety study of transitioning parenteral Prostacyclin Analogs to Selexipag in Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2020
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- 15 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association